A phase Ib trial with a 4-week subcutaneous administration of either 10 mg or 15 mg tirzepatide once weekly in subjects with T2D led to a significant reduction in fasting plasma glucose concentrations (LSM difference [95% CI]: 49.12 mg/dl [78.14, 20.12] and 43.15 mg/dl [73.06, 13.21], respectively) and to reductions in body weight (LSM difference [95% CI]: 2.62 kg [3.79, 1.45] and 2.07 kg [3.25, 0.88], respectively
Gallbladder disease Tirzepatide has been associated with an increased risk of gallbladder disease
This article covers the mechanics you need to understand how formularies get built, how rebate contracts work in practice, what PBMs do with the money they extract, and how the regulatory climate of 20252026 is forcing a renegotiation of those mechanics
The advice felt a little more actionable than some others Ive tried
Her announcement sparked a lot of chatter amongst different groups, driving the message that even world class athletes with disciplined workout routines may need to turn to GLP-1s for their needs
